David Duplat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Duplat has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Camila González
Centro de Investigaciones en Microbiología y Parasitología Tropical, CIMPAT, Departamento de Ciencias Biológicas, Universidad de los Andes, Cra. 1 N° 18a-12, Bogotá 111711, Colombia
2 shared publications - Paula Benitez-Bolivar
Centro de Investigaciones en Microbiologia y Parasitologia Tropical (CIMPAT), Department of Biological Sciences, Universidad de los Andes, Bogota, Colombia
2 shared publications Seray Cicek
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsTony Mazzulli
Department of Microbiology, University Health Network/Sinai Health System, Toronto, M5G 1X5 Ontario, Canada
2 shared publicationsYuxiu Guo
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
2 shared publications- Abelardo Silva-Júnior
Laboratório de Pesquisas em Virologia e Imunologia ‐ LAPEVI, Instituto de Ciências Biológicas e da Saúde ‐ ICBS Universidade Federal de Alagoas Maceió Alagoas Brazil
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaeb7039
International multisite implementation of distributed cell-free protein biomanufacturing to advance health and research equity
Limitations in global access to research and health care capacity undermine equity, sustainability, and resilience, particularly in resource-limited settings. Molecular diagnostics and biologic therapeutics are set to revolutionize medicine; however, our dependence on centralized biomanufacturing and cold chain logistics restricts access to these benefits. These constraints reflect a chronic and unmet global challenge. Here, with research teams in North and South America and Asia, we challenge the top-down paradigm by advancing community-driven solutions that empower underserved populations to participate in the bioeconomy, producing what they need, when, and where they need it. Our approach leverages low-burden biomanufacturing—built on cell-free protein synthesis and open-source hardware—to enable local, on-demand production of high-value bioproducts, including growth factors, vaccines, and diagnostic enzymes, demonstrating performance comparable to commercial gold standards. Implemented at 10 sites worldwide, this platform supported patient trials targeting globally relevant pathogens. Together, these efforts lay the foundation for a globally inclusive biomanufacturing ecosystem, where innovation goes beyond geographic boundaries.
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaeb7039
Open AccessInternational multisite implementation of distributed cell-free protein biomanufacturing to advance health and research equity
Limitations in global access to research and health care capacity undermine equity, sustainability, and resilience, particularly in resource-limited settings. Molecular diagnostics and biologic therapeutics are set to revolutionize medicine; however, our dependence on centralized biomanufacturing and cold chain logistics restricts access to these benefits. These constraints reflect a chronic and unmet global challenge. Here, with research teams in North and South America and Asia, we challenge the top-down paradigm by advancing community-driven solutions that empower underserved populations to participate in the bioeconomy, producing what they need, when, and where they need it. Our approach leverages low-burden biomanufacturing—built on cell-free protein synthesis and open-source hardware—to enable local, on-demand production of high-value bioproducts, including growth factors, vaccines, and diagnostic enzymes, demonstrating performance comparable to commercial gold standards. Implemented at 10 sites worldwide, this platform supported patient trials targeting globally relevant pathogens. Together, these efforts lay the foundation for a globally inclusive biomanufacturing ecosystem, where innovation goes beyond geographic boundaries.
- Open Access
- 11 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0268340
Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application
Continued waves, new variants, and limited vaccine deployment mean that SARS-CoV-2 tests remain vital to constrain the coronavirus disease 2019 (COVID-19) pandemic. Affordable, point-of-care (PoC) tests allow rapid screening in non-medical settings. Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) is an appealing approach. A crucial step is to optimize testing in low/medium resource settings. Here, we optimized RT-LAMP for SARS-CoV-2 and human β-actin, and tested clinical samples in multiple countries. “TTTT” linker primers did not improve performance, and while guanidine hydrochloride, betaine and/or Igepal-CA-630 enhanced detection of synthetic RNA, only the latter two improved direct assays on nasopharygeal samples. With extracted clinical RNA, a 20 min RT-LAMP assay was essentially as sensitive as RT-PCR. With raw Canadian nasopharygeal samples, sensitivity was 100% (95% CI: 67.6% - 100%) for those with RT-qPCR Ct values ≤ 25, and 80% (95% CI: 58.4% - 91.9%) for those with 25 < Ct ≤ 27.2. Highly infectious, high titer cases were also detected in Colombian and Ecuadorian labs. We further demonstrate the utility of replacing thermocyclers with a portable PoC device (FluoroPLUM). These combined PoC molecular and hardware tools may help to limit community transmission of SARS-CoV-2.
- 11 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0268340
Open AccessMulticenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application
Continued waves, new variants, and limited vaccine deployment mean that SARS-CoV-2 tests remain vital to constrain the coronavirus disease 2019 (COVID-19) pandemic. Affordable, point-of-care (PoC) tests allow rapid screening in non-medical settings. Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) is an appealing approach. A crucial step is to optimize testing in low/medium resource settings. Here, we optimized RT-LAMP for SARS-CoV-2 and human β-actin, and tested clinical samples in multiple countries. “TTTT” linker primers did not improve performance, and while guanidine hydrochloride, betaine and/or Igepal-CA-630 enhanced detection of synthetic RNA, only the latter two improved direct assays on nasopharygeal samples. With extracted clinical RNA, a 20 min RT-LAMP assay was essentially as sensitive as RT-PCR. With raw Canadian nasopharygeal samples, sensitivity was 100% (95% CI: 67.6% - 100%) for those with RT-qPCR Ct values ≤ 25, and 80% (95% CI: 58.4% - 91.9%) for those with 25 < Ct ≤ 27.2. Highly infectious, high titer cases were also detected in Colombian and Ecuadorian labs. We further demonstrate the utility of replacing thermocyclers with a portable PoC device (FluoroPLUM). These combined PoC molecular and hardware tools may help to limit community transmission of SARS-CoV-2.